Johnson & Johnson Reports Phase 3 extension Data for Talazoparib in Urothelial carcinoma

Johnson & Johnson today announced Phase 3 extension results for talazoparib in patients with urothelial carcinoma. The study demonstrated that talazoparib demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of urothelial carcinoma and support the continued development of talazoparib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.